75747-14-7 | 17-AAG (tanespimycin)

Chemical type

• Semisynthetic C-17 amino-substituted derivative of geldanamycin

^[1]

• HSP-90 (heat shock protein-90) inhibitor

^[2]

Key properties

• More stable than geldanamycin
• Inhibits Hsp90
• Poorly soluble leading to formulation issues
• Hepatotoxicity observed in clinical trials
• Lower reduction potential reduces toxicity compared to parent compound
• Higher binding affinity to tumor cell Hsp90

^[1]

• Inhibits HSP-90 to promote apoptosis
• Down-regulates Bcr-Abl levels and NF-κB expression
• Upregulates p53, caspase-3, caspase-8, and caspase-9
• Induces intrinsic and extrinsic apoptotic pathways
• Proapoptotic in leukemia and colon cancer cells

^[2]

• Investigated in clinical trials for cancers including melanoma, multiple myeloma, gastrointestinal stromal tumors, prostate cancer, non-small cell lung cancer, and HER2-positive breast cancer

^[1]

• Chemotherapeutic agent for colorectal cancer
• Combination therapy with capecitabine and irinotecan
• Apoptosis inducer in HT-29 colon cancer cells
• HSP-90 targeted therapy to overcome chemoresistance

^[2]

Classification by use

• Hsp90 inhibitors
• Anticancer agents

^[1]

• Chemicals used as apoptosis inducers
• Chemicals used in cancer chemotherapy
• Chemicals used as HSP inhibitors

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry, Journal of Medicinal Chemistry, Volume 67, Issue 20, 24 October 2024, Pages 17946-17963
2. [Cite:2] Combination effects of Irinotecan, irinotecan and 17-AAG on colorectal cancer cell line (HT-29), Annals of Medicine and Surgery, Volume 78, June 2022, 103850